Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP10 | Q14694 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | USP13 | Q92995 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 0.67 |
| ▸ | CNR2 | P34972 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 6/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.56 |
| ▸ | GALR3 | O60755 | 1/20 | 0.55 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359604 | 1.00 | USP10 (1.00) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL13170963 | 0.92 | USP10 (0.84) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921341 | 0.92 | USP10 (0.84) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL13192047 | 0.89 | USP10 (0.80) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921506 | 0.89 | USP10 (0.80) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL7469214 | 0.87 | USP10 (0.76) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921355 | 0.84 | USP10 (0.71) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921511 | 0.83 | USP10 (0.70) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921345 | 0.82 | USP10 (0.69) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL17557755 | 0.81 | CNR1 (1.00) | USP10PIK3C3USP13CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024136338-A1 | COMPOSITION COMPRISING N-BENZYLQUINAZOLINE-4-AMINE COMPOUND FOR PREVENTING OR TREATING OBESITY OR LIPID-ASSOCIATED METABOLIC DISORDERS | 연세대학교 산학협력단 | 2024-06-27 | — | — | WO | claimed |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | claimed |
| WO-2020223609-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY (US) | 2020-11-05 | — | — | WO | claimed |
| US-20200165608-A1 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | NATIONAL SCIENCE FOUNDATION | 2020-05-28 | — | — | US | claimed |
| US-20190247397-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | THE JOHNS HOPKINS UNIVERSITY | 2019-08-15 | — | — | US | claimed |
| EP-3515448-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | The Johns Hopkins University (US) | 2019-07-31 | — | — | EP | claimed |
| WO-2018057834-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-03-29 | — | — | WO | claimed |
| WO-2014083327-A1 | ADENINE DERIVATIVES SUITABLE FOR THE TREATMENT OF (INTER ALIA) MUSCULAR DYSTROPHY | MD PHARMA AB (SE) | 2014-06-05 | — | — | WO | claimed |
| CN-103623033-A | Euphorbiaceae plant active substance for inhibiting cancer and/or tumor cell growth and application thereof | SBC VIRBAC BIOTECH CO LTD | 2014-03-12 | — | — | CN | claimed |
| US-12303508-B2 | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2025094946-A1 | ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, KIT FOR TREATMENT OF CANCER, AND COMPOSITION FOR TREATMENT OF CANCER | 国立大学法人東海国立大学機構 | 2025-05-08 | — | — | WO | disclosed |
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | CORNERSTONE PHARMACEUTICALS INC (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2024210503-A1 | COMPOSITION CONTAINING USP10 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF OBESITY AND LIPID-RELATED METABOLIC DISEASES | 연세대학교 산학협력단 | 2024-10-10 | — | — | WO | disclosed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20120258975-A1 | Potent Small Molecule Inhibitors of Autophagy, and Methods of Use Thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2012-10-11 | — | — | US | disclosed |
| WO-2012079079-A1 | PRODUCTION OF INDUCED PLURIPOTENT STEM CELLS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012079079-A1 | PRODUCTION OF INDUCED PLURIPOTENT STEM CELLS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-06-14 | — | — | WO | disclosed |
| EP-2456761-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND METHODS OF USE THEREOF | President and Fellows of Harvard College (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011011522-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011522-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | PDK4, PDK2, PDK1 | USP10 2545/4885PIK3C3 578/4885USP13 2772/4885 |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | MCL1, BAX, CASP3 | USP10 1145/4885PIK3C3 3684/4885USP13 1603/4885 |
| US-12303508-B2 | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | ACAT1, PARP1, POLRMT | USP10 2902/4885PIK3C3 1403/4885USP13 3347/4885 |
| US-20120258975-A1 | Potent Small Molecule Inhibitors of Autophagy, and Methods of Use Thereof | ATG7, BECN1, SQSTM1 | USP10 1695/4885PIK3C3 186/4885USP13 2044/4885 |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | USP10 2874/4885PIK3C3 4609/4885USP13 3056/4885 |
| US-20190247397-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | ACAT1, PARP1, POLRMT | USP10 2902/4885PIK3C3 1403/4885USP13 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.